| Targets |
m-PEG12-OTs does not target a specific biological receptor but serves as a chemical linker in PROTAC synthesis. The tosylate group is a good leaving group that can be displaced by nucleophiles (e.g., amines, thiols) to form stable linkages. In PROTAC design, the PEG linker connects an E3 ubiquitin ligase ligand with a target protein ligand, enabling selective protein degradation via the ubiquitin-proteasome system. The 12-unit PEG chain provides flexibility and aqueous solubility.
|
|---|---|
| ln Vitro |
In vitro, m-PEG12-OTs is used as a building block in the synthesis of PROTAC molecules. The tosylate group allows for facile substitution reactions to introduce various functional groups or to attach to other molecular components. The PEG12 spacer provides optimal length and hydrophilicity for PROTAC applications, facilitating the spatial arrangement required for efficient ternary complex formation between the target protein, PROTAC, and E3 ubiquitin ligase.
|
| ln Vivo |
In vivo activity is not directly applicable for m-PEG12-OTs as it is a chemical linker used in PROTAC synthesis, not a therapeutic compound itself. The PROTACs synthesized using this linker are then evaluated in vivo for targeted protein degradation and therapeutic efficacy. The PEG12 linker contributes to the overall pharmacokinetic properties of the final PROTAC molecule, including solubility, stability, and bioavailability.
|
| Enzyme Assay |
Non-cellular assays for m-PEG12-OTs involve characterizing its chemical properties and reactivity. The tosylate group's reactivity can be assessed by monitoring substitution reactions with nucleophiles using HPLC or NMR spectroscopy. The compound's purity is confirmed by HPLC, and its structure is verified by mass spectrometry and NMR. Binding interactions are not applicable as this is a chemical linker.
|
| Cell Assay |
In vitro cellular experiments are not performed with m-PEG12-OTs directly, as it is a synthetic intermediate. Rather, the PROTACs synthesized using this linker are tested in cellular assays to assess target protein degradation (by Western blotting), downstream signaling effects, and cell viability. The PEG12 linker's contribution to PROTAC cellular activity is evaluated through structure-activity relationship studies.
|
| Animal Protocol |
In vivo animal experiments are performed with PROTACs synthesized using m-PEG12-OTs, not with the linker itself. These studies are conducted in murine xenograft models to evaluate the antitumor efficacy, pharmacokinetics, and safety of the final PROTAC molecules. The PEG12 linker influences the overall pharmacokinetic properties and biodistribution of the PROTAC.
|
| ADME/Pharmacokinetics |
m-PEG12-OTs has a molecular formula of C32H58O15S and a molecular weight of 714.86. The CAS number is 2103241-71-8. The compound is stored as a powder at -20°C for up to 3 years. In solvent, it is stable at -80°C for up to 1 year. It is typically shipped with blue ice or at ambient temperature. Purity is typically ≥95%. The compound is soluble in DMSO and other organic solvents.
|
| Toxicity/Toxicokinetics |
Toxicity data for m-PEG12-OTs are limited as it is a research reagent used in PROTAC synthesis, not a therapeutic agent. Standard laboratory safety precautions should be followed when handling this compound. The tosylate group may cause skin and eye irritation. The compound is for research use only and not for human therapeutic applications. Researchers should consult the safety data sheet for specific handling and disposal guidelines.
|
| References | |
| Additional Infomation |
m-PEG12-OTs is also known as m-PEG12-Ots. The tosylate (p-toluenesulfonate) group serves as a versatile leaving group for nucleophilic substitution reactions. The compound is classified as a PEG-based PROTAC linker. It is suitable for use in the synthesis of PROTAC molecules for targeted protein degradation research. All products are for research use only and not for human use.
|
| Molecular Formula |
C32H58O15S
|
|---|---|
| Molecular Weight |
714.86
|
| Exact Mass |
714.35
|
| CAS # |
2103241-71-8
|
| PubChem CID |
102452405
|
| Appearance |
Colorless to off-white liquid
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
38
|
| Heavy Atom Count |
48
|
| Complexity |
748
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC
|
| InChi Key |
PKDDJAWVDLQTTD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H58O15S/c1-31-3-5-32(6-4-31)48(33,34)47-30-29-46-28-27-45-26-25-44-24-23-43-22-21-42-20-19-41-18-17-40-16-15-39-14-13-38-12-11-37-10-9-36-8-7-35-2/h3-6H,7-30H2,1-2H3
|
| Chemical Name |
2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3989 mL | 6.9944 mL | 13.9888 mL | |
| 5 mM | 0.2798 mL | 1.3989 mL | 2.7978 mL | |
| 10 mM | 0.1399 mL | 0.6994 mL | 1.3989 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
